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abstract
Keywords:

Highly active antiretroviral therapy (HAART) has been successful in reducing human immu-

Entry inhibitor

nodeficiency virus (HIV)-1-associated morbidity and mortality since its introduction in 1996.

Highly active antiretroviral therapy

However, it fails to eradicate HIV-1 infection. The high cost of life-long highly active antiretro-

Human immunodeficiency virus

viral therapy and the emergence of drug resistance among HIV-1-infected individuals have

Sanguisorba officinalis

brought renewed pressure for the discovery of novel antivirals and alternative medicines.

Traditional Chinese medicine

Traditional Chinese medicine (TCM) is a complementary and alternative medicine, and serves
as a rich resource for new drug development. Despite the almost 100 plant-derived compounds
that are in clinical trials, few target HIV-1 infection. In this study, we discovered that Sanguisorba
officinalis extract (SOE) has anti-HIV-1 properties. Using a cell-based assay and single-cycle
luciferase reporter viruses pseudotyped with envelopes from HIV-1 or control viruses, we
found that SOE exhibited significant inhibitory ability against both CCR5 and CXCR4 tropic HIV-1
(ADA and HXB2), with respective IC50 values of 1.91  0.16 mg/mL and 3.70  0.53 mg/mL. SOE also
inhibited simian immunodeficiency virus infection but failed to block vesicular stomatitis virus,
severe acute respiratory syndrome coronavirus, and influenza H5N1 pseudoviruses. Furthermore, we showed that SOE had no effect on postentry events of HIV-1 replication. Because SOE
pretreatment with the virus but not with cell lines expressing viral receptors showed the
maximal inhibitory activity, we can state that SOE probably blocks entry by acting on the viral
envelope directly. In addition, SOE was able to inhibit reverse transcriptase inhibitor resistant
viruses (K103N, Y188L, and K103N/Y188L/G190A) and a protease inhibitor resistant strain (PI2840). Our findings demonstrate SOE as a novel and specific entry inhibitor, which sheds light on
the discovery of anti-HIV-1 drugs from traditional herbal medicines.
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Introduction

Traditional Chinese medicine (TCM) includes various forms of
herbal medicine, acupuncture, moxibustion, massage, Qi exercise, meditation, and dietary therapy. TCM was developed in
China as a personalized medical practice based on a tradition
of more than 5000 years. As a result, thousands of plants have
been used as herbal medicines for treating different types of
diseases. For example, one of the most famous drugs, artemisinin, was originally extracted from the plant Artemisia
annua and is now a standard treatment worldwide for Plasmodium falciparum malaria [1]. During the past decade, the use
of TCM has increased globally as one of the mainstreams of
complementary and alternative medicine. It also serves as a
rich resource for new drug development.
Prior to the availability of highly active antiretroviral
therapy (HAART), people with human immunodeficiency
virus (HIV)/AIDS often sought herbal therapy in China. This
situation continues today because HAART is still not readily
accessible or affordable especially in rural areas, where the
majority of patients reside. Even in the era of HAART, HIVinfected people who used herbal therapy at a high rate
sought more frequent visits to TCM providers and reported
helpful improvement with the treatment [2,3]. In most cases,
however, it remains unknown whether the herbs used had
any anti-HIV activities, and therefore it is unknown if they
were regarded as enhancing patients’ immune function, as
the treatment of HIV-related symptoms, or as the

Materials and methods

2.1.

Preparation of SOE

The stem of S. officinalis was cut into small pieces and
immersed in distilled water. The mixture was treated by ultrasound for 1 hour, followed by boiling twice at 100 C for 30
minutes. After filtration, the supernatant was concentrated
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management of HAART-related side effects [4]. In recent
years, studies have demonstrated that evidence-based
research on compounds extracted from herbal plants can
elucidate their biochemical activity, revealing antitumor activity in some cases and anti-HIV activity in others [5e9]. The
study of some herbal compounds has been moved forward
into clinical trials [6,7,10]. Prior to this study, however, it was
unclear if Sanguisorba officinalis had any anti-HIV activity.
Sanguisorba officinalis (also called Great Burnet) is a plant in
the family Rosaceae, subfamily Rosoideae. It is easily found in
the northern regions of China and has been used as TCM for
thousands of years to treat hemostasis and inflammation [11].
Some other functions that have been discovered in recent
years include its antioxidant and antitumor properties
[12e14].To the best of our knowledge, we are the first group to
study the anti-HIV-1 activities of the extract of S. officinalis
(SOE). Our findings have implications for exploring TCM for
new antiviral discoveries.
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Fig. 1 e Activity of Sanguisorba officinalis extract (SOE) against HIV-1ADA, HIVHxB2, and HIVVSV. Serially diluted SOE was added
to GHOST-CCR5 and GHOST-CXCR4 infected with (A) HIV-1ADA and (B) HIVHxB2, respectively. HIVVSV was tested as a negative
control. The luciferase level was measured 2 days postinfection. All results are means ± standard errors of the means from
three independent experiments. To test SOE cytotoxicity, (C) GHOST(3)-CD4-CCR5 and (D) GHOST(3)-CD4-CXCR4 cells
were cultured in serially diluted SOE at 37 C for 48 hours in 5% CO2. Cell viability was then measured using the Promega
CellTiter-Glo Luminescent Cell Viability Assay kit. The data represent the mean ± standard deviation of triplicate
experiments.
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by a rotary evaporator under reduced pressure, followed by
lyophilization for 48 hours to obtain the aqueous extract
powder (SOE). The yield of SOE was 9.9e11.2%. Highperformance liquid chromatography analysis of SOE was
conducted on an Ultimate AQ-C18 column (250 mm 
4.6 mm, 5 m)(Welch, Shanghai, China). The mobile phase
consisted of acetonitrile (A) and 0.2% formic acid (B) in water,
using a gradient elution of 5e15% A at 0e10 minutes, 15%e
25% A at 10e25 minutes, 25%e30% A at 25e35 minutes, 30%e
70% A at 35e45 minutes, 70%e95% A at 45e50 minutes, and
95% A at 50e60 minutes. The solvent velocity of flow was
1.0 mL/minute and the column was at room temperature.
The detection wavelength was set at 254 nm. The contents of
each component were controlled between 1.25% and 1.35%
and 1.69% and 1.80%, respectively. The extract powder was
dissolved in phosphate buffered saline and passed through
0.45 mm filter for sterilization. SOE was dissolved in dimethyl
sulfoxide at a concentration of 40 mg/mL, followed by gentle
vortex at room temperature. The supernatants were carefully collected after centrifugation at 3000g for 5 minutes
and filtered through a 0.22 mm Millipore syringe filter for
experiments.

2.2.

Cell culture and virus generation

The cell lines 293T, MDCK, and HEK293T-ACE2 were cultured in
Dulbecco’s modified Eagle medium with 10% inactivated
fetal bovine serum (Invitrogen), 100 units/mL penicillin, and
100 mg/mL streptomycin sulfate (Invitrogen). GHOST(3)-CD4CCR5/CXCR4 cells were obtained from the US National Institutes of Health (NIH, Bethesda, MA, USA) AIDS Research and
Reference Reagent Program and cultured in Dulbecco’s modified Eagle medium with 10% fetal bovine serum, 100 units/mL
penicillin, 100 mg/mL streptomycin sulfate, 100 mg/mL
hygromycin B, 500 mg/mL G418, and 1 mg/mL puromycin (Sigma
Aldrich). Single-cycle luciferase HIVADA, HIVHxB2, simian immunodeficiency virus (SIV)mac239, SIVmac1a11 vesicular stomatitis virus (VSV), H5N1anhui, and severe acute respiratory
syndrome coronavirus (SARS-CoV) pseudoviruses were constructed as described previously [9,15e17]. Briefly, pseudoviruses were generated by co-transfection of 293T cells (using
polyethylenimine; Polysciences Inc., Warrington, PA, USA)
with NL4-3 EeVe Lucþ and envelope protein from different
strains of viruses. All non-nucleoside reverse-transcriptase
inhibitor (NNRTI) mutant constructs were generated based on
a molecular clone backbone NL4-3 EeVe Lucþ, as we previously described [8]. The protease-inhibitor resistant strain (PI2840) was obtained from NIH (resistant to multiple anti-HIV
protease drugs; carrying L10R, M46I, L63P, V82T, and I84V).
Cell-free supernatant was collected 48 hours post-transfection
and frozen at 80 C. The 50% tissue culture infective dose was
calculated as described previously [8].

2.3.

Cell viability assay

GHOST(3)-CD4-CCR5/CXCR4 cells were incubated in the
presence or absence of serially diluted SOE at 37 C in 5% CO2
for 48 hours. Cell viability was then measured using a
commercially available kit (CellTiter-Glo Luminescent Cell
Viability Assay kit; Promega, USA).

2.4.

Antiviral assay

The inhibitory activities of the SOE against viruses were
evaluated as described previously [8]. Briefly, a serially diluted
drug was tested against virus infection at 50% tissue culture
infective dose. GHOST(3)-CD4-CCR5/CXCR4 were used for
HIVADA, HIVHxB2, SIVmac239 and SIVmac1a11, whereas MDCK and
HEK293T-ACE2 were used for H5N1 and SARS-CoV pseudovirus infection, respectively. The viral infection was determined
on Day 3 by measuring the reporter luciferase activity in target
cells postinfection using commercially available kits. Antiviral
data are reported as the quantity of drug required to inhibit
viral production by 50% (EC50).

2.5.

Fractionation of aqueous SOE

Different polar solvents were used to obtain subfractions from
SOE yielding petroleumeether-partitioned extract (PE), ethylacetate-partitioned extract (EtOAc), n-butanol-partitioned
extract (BuOH), and water residues. These subfractions were
then concentrated in a vacuum dryer for later testing.

3.

Results

3.1.

Anti-viral activity of aqueous SOE

To determine the antiviral activity of SOE, GHOST-CCR5 and
GHOST-CXCR4 cells were infected with CCR5-tropic HIV-1ADA
and CXCR4-tropic HIV-1HxB2, respectively, in the presence of
serial diluted SOE. As a control, VSV pseudovirus was included
in parallel experiments. As shown in Fig. 1A and B, SOE displayed an EC50 of 1.91  0.16 mg/mL and 3.70  0.53 mg/mL in
the inhibition of HIV-1 replication of both coreceptor tropisms
without observed cell toxicity (Fig. 1C and D). By contrast,
when SOE was tested against VSV pseudovirus infection, no
inhibition was observed. Because ADA, HXB2, and VSV pseudoviruses share the same HIV backbone and differ only in the
glycoproteins expressed on the viral surface, this result suggests that SOE acts specifically in inhibiting HIV-1 replication
at an early stage of viral entry.

3.2.

No effect of SOE on HIV-1 postentry

To confirm that SOE antagonizes viral entry rather than
postentry events, we tested the same panel of viruses but with
a modified experimental schedule. Target cells were first coincubated with pseudovirus for 2 hours, washed, and then
treated with the presence of 50 mg/mL SOE or 1 mM AZT, which
is a potent NNRTI, for 48 hours. As shown in Fig. 2A, with this
experimental schedule, SOE does not strongly inhibit HIV-1
anymore, as compared with AZT. This result supports the
finding that inhibition of SOE on HIV-1 replication is not due to
the blockade at the postentry step (e.g., reverse transcription)
but rather at an entry step.

3.3.

SOE inhibits HIV-1 directly

To determine whether SOE inhibits virus entry by directly
inactivating HIV-1 or binding to its receptor on target cells,
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Fig. 2 e Sanguisorba officinalis extract (SOE) inhibits HIV-1
infection by binding to the viral envelope and blocking
entry of the virus. (A) Post entry assay. GHOST-CD4-CCR5
or CXCR4 cells were coincubated with pseudovirus for 2
hours, washed, and then treated with the presence of 50
mg/mL SOE, dimethyl sulfoxide (DMSO) as negative control
and 1 mM AZT as positive control for 48 hours. SOE does not
inhibit either HIV-1ADA or HIVHxB2 virus gene replication
after viral entry is achieved. (B) SOE-virus interaction
assay. HIV-1ADA and HIVHxB2 pseudovirus pre-treated with
50 mg/mL SOE or DMSO as a negative control and entry
inhibitor enfuvirtide (T-20) as a positive control. SOE
pretreatment inhibited both HIVADA and HIVHxB2
pseudovirus infection to a similar degree as T-20. (C) SOEcell binding assay. GHOST cells were pretreated with SOE
or the CCR5 antagonist maraviroc and the CXCR4
antagonist JM2987 as positive controls, and DMSO as
negative control for 1 hour at 37 C prior to being infected
with HIV-1ADA or HIV-1HxB2. SOE pretreatment with the
cells had no antiviral effect, whereas maraviroc and
JM2987 pretreatment showed strong inhibition against
HIV-1 ADA and HXB2 pseudoviruses at 1 mM, as expected.
The data represent the mean ± standard deviation of
triplicate experiments.

SOE-virus binding and SOE-cell binding assays were performed. In the SOE-virus binding assay, pseudovirus was
pretreated with 50 mg/mL SOE first. In the meantime, dilution
solution dimethyl sulfoxide was used as a negative control
and entry inhibitor enfuvirtide (T-20) as a positive control. The
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Fig. 3 e Activity of Sanguisorba officinalis extract (SOE)
against simian immunodeficiency virus (SIV), influenza,
and severe acute respiratory syndrome coronavirus (SARSCoV). Serially diluted SOE was added to (A) GHOST-CCR5
infected with SIVmac239, and SIVmac1A11, (B) 293T-ACE2
infected with SARS-CoV, and (C) MDCK cells infected with
H5N1Anhui. (B,C) HIVHxB2 was tested as a positive control in
GHOST-CXCR4 cells. The luciferase level was measured 2
days postinfection. All results are means ± standard errors
of the means from three independent experiments.

viruses were then recovered by ultracentrifugation and used
to infect target cells. We found that SOE inhibited both ADA
and HXB2 pseudovirus infection to a similar degree as T-20,
which blocks HIV-1 fusion (Fig. 2B). Subsequently, the SOE-cell
binding assays were performed by pretreating the target
GHOST cells with SOE or with the CCR5 antagonist maraviroc
(MVC) and CXCR4 antagonist JM2987 as positive controls for 1
hour at 37  C. After washing with phosphate buffered saline,
cells were incubated with HIV-1ADA or HIV-1HxB2 for 2 hours,
washed, and cultured at 37 C for 48 hours [18]. We found that
pretreating the target cells with SOE had virtually no antiviral
effect, whereas MVC and JM2987 showed strong inhibition
against the respective ADA and HXB2 pseudoviruses at 1mM as
expected (Fig. 2C). This demonstrates that SOE inhibits HIV-1
infection by acting on the viral envelope glycoprotein gp160,
which mediates viral entry into the host target cells.
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Fig. 4 e Activity of Sanguisorba officinalis extract (SOE) against non-nucleoside reverse-transcriptase inhibitor (NNRTI)
mutant pseudovirus and a protease-inhibitor resistant strain. (A) Serially diluted SOE was added to GHOST-CCR5 and
GHOST-CXCR4 infected with NNRTI mutant pseudoviruses (K103N, Y188L and K103N/Y188L/G190A) and a proteaseinhibitor resistant strain (PI-2840), respectively. (B) Nevirapine (NVP) was included as control. All NNRTI mutant constructs
were generated based on a molecular clone backbone, pNL4-3LucEnvVpr. The PI-2840 strain (resistant to multiple anti-HIV
protease drugs) carries L10R, M46I, L63P, V82T, and I84V. The luciferase level was measured 2 days postinfection. All results
are means ± standard errors of the means from three independent experiments.

3.4.
Antiviral activity of SOE against SIV, influenza
H5N1, and SARS-CoV pseudoviruses
To further confirm that SOE is a HIV-1-specific entry inhibitor,
we tested two SIV, one influenza H5N1 and one SARS-CoV
pseudoviral strain. A previous study indicated that residue
peptides were found to be potent inhibitors of virus entry
against both HIV-1 and SIV envelope glycoproteins [19].
Interestingly, SOE inhibited both SIV strains mac239 and
mac1A11, but neither influenza H5N1 nor SARS-CoV (Fig. 3).
These results suggest that SOE has a broad and specific reactivity against diverse AIDS viruses.

3.5.
Antiviral activity of SOE against drug resistant
HIV-1 strains
The rapid emergence of drug-resistant strains of HIV-1 in
patients is one of the major obstacles to successful antiretroviral treatment. Therefore, an experiment involving antiHIV resistant viruses was carried out in which four HIV-1
drug-resistant strains were tested, including three NNRTI
resistant viruses (K103N, Y188L, and K103N/Y188L/G190A) and
one protease inhibitor resistant virus (PI-2840) [8]. As expected, SOE inhibited all four drug-resistant strains (Fig. 4A),
demonstrating greater breadth of inhibition when compared
to nevirapine, which is a United States Food and Drug
Administration-approved NNRTI. Consistent with previous
findings, nevirapine did not inhibit HIV-1 resistant strains
harboring Y188L or K103N/Y188L/G190A mutations (Fig. 4B).
Because viral entry precedes reverse transcription, these results provide further support for SOE as an entry inhibitor
against live replicating HIV-1 strains.

3.6.

Anti-HIV activities fractionation of SOE

To further characterize the anti-HIV activity of aqueous SOE,
the extracts were subjected to different polar solvents to
obtain PE, EtOAc, BuOH, and water residues. Each fraction was

vacuum dried and then screened for anti-HIV-1 activity. The
EtOAc and BuUOH subfractions strongly diminished HIV-1
infection of target cell lines similar to SOE (Figs. 1 and
5AeD). However, the PE subfraction did not show any inhibition of HIV-1. These results indicate that the solubility of SOE
is dependent on the polarity of the solvent, which provides
direction for future isolation of small molecule HIV-1 entry
inhibitors from these subfractions.

4.

Discussion

In this study, we demonstrated that SOE blocks the entry of
both CCR5-tropic and CXCR4-tropic strains of HIV-1. This
blockade is HIV-1 specific because SOE does not exhibit any
activities against HIV-Lucþ viruses pseudotyped with envelopes of VSV, SARS-CoV, and influenza. Interestingly, SOE acts
directly on HIV-1 instead of cellular receptors or coreceptors.
It also exhibits potency against replication competent HIV-1
strains resistant to specific drugs targeting protease and
reverse transcriptase (RT) activities. Our findings therefore
provide scientific evidence for the potential use of SOE in the
prevention and treatment of HIV-1 infection and the search
for small molecular compounds as specific entry inhibitors.
Stopping HIV-1 from entering target cells is a critical
strategy for both prevention and treatment [20,21]. Until now,
there have been only two drugs in this category approved by
the FDA for clinical use in the market: MVC and T-20. MVC
binds to the host CCR5 coreceptor to prevent binding with
gp120, whereas T-20 interacts with gp41 to interrupt membrane fusion between HIV-1 and the host target cell plasma
membrane. T-20 is part of the repertoire of antiretroviral
drugs that have been used in combination therapy to treat
HIV-1 infection [22]. Although effective, T-20 has to be
administrated by injection, whereas MVC requires the
screening of patients to exclude strains of CXCR4-tropism. It is
therefore useful to identify new types of HIV-1 entry inhibitors. To this end, it is of great interest to discover that SOE

S57

j o u r n a l o f f o o d a n d d r u g a n a l y s i s 2 1 ( 2 0 1 3 ) s 5 2 es 5 8

SOE-EtOAc
100

100

ADA
HXB2
VSV

80
60
40

60
40
20

0

0
12
.5
00
6.
25
0
3.
12
5
1.
56
0
0.
78
0
0.
39
0
0.
19
5
0.
09
8

20

Concentration (µg/mL)

Concentration (µg/mL)

ADA
HXB2
VSV

80
60
40

SOE-DW
100

60
40

0

0
50
.0
0
25 0
.0
00
12
.5
00
6.
25
0
3.
12
5
1.
56
0
0.
78
0
0.
39
0
0.
19
5
0.
09
8

20

Concentration (µg/mL)

ADA
HXB2
VSV

80

20

12
.5
00
6.
25
0
3.
12
5
1.
56
0
0.
78
0
0.
39
0
0.
19
5
0.
09
8

% Inhibition

D

SOE-BUOH
100

% Inhibition

C

ADA
HXB2
VSV

80

12
.5
00
6.
25
0
3.
12
5
1.
56
0
0.
78
0
0.
39
0
0.
19
5
0.
09
8

% Inhibition

B

SOE-PE

% Inhibition

A

Concentration (µg/mL)

Fig. 5 e Activity of fractions of Sanguisorba officinalis extract against HIV-1ADA, HIVHxB2, and HIVVSV. Serially diluted (A)
petroleumeether-partitioned extract (PE), (B) ethyl-acetate-partitioned extract (EtOAc), (C) n-butanol-partitioned extract
(BuOH), or (D) distilled water (DW) fractions were added to GHOST-CCR5 and GHOST-CXCR4 infected with HIV-1ADA, HIVHxB2,
and HIVVSV. The luciferase level was measured 2 days postinfection. All results are means ± standard errors of the means
from three independent experiments.

is capable of inhibiting entry of both CCR5- and CXCR4-tropic
HIV-1 ADA and HXB2 strains, as well as of SIVmac1A11 and
SIVmac239, by binding viral envelope glycoproteins directly. It
has previously been shown that despite a significant level of
sequence diversity, HIV-1 and SIV share a series of events
during virus entry including binding of gp120 to CD4 and
chemokine coreceptor, and fusion between viral and cellular
membranes [20,23e25]. SOE probably acts upon a highly
conserved element of HIV-1 and SIV envelope glycoproteins,
an issue that still requires future investigation [23,24,26e28].
Because SIVmac1A11 enters target cells in a CD4-independent
way [16], SOE probably inhibits virus entry through other
mechanisms rather than by blocking the CD4 binding site
directly. Critically, the proven anti-HIV-1 specificity, together
with the lack of antiviral effects against VSV, SARS-CoV, and
influenza, also rule out the possibility that SOE simply inactivates the HIV-1 virus by acting on viral lipids like a disinfectant. In support of our findings, several small molecules
isolated from plants have been reported to have some moderate inhibitory ability against HIV-1 entry. For example,
polyphenols found in green tea probably interrupt membrane
fusion between HIV-1 and the host cell plasma membrane
[29]. Further investigations, are necessary to reveal the mode
of SOE action, which may lead to the identification of a new
drug targeting the HIV-1 envelope.
With the enhanced efforts in treatment as prevention,
there is also the issue of rapid emergence of drug-resistant

strains of HIV-1, especially in developing countries [30].
Although several extracts of herbal medicines have been
investigated for their anti-HIV activities, inhibition of anti-HIV
drug-resistant strains was rarely studied [7,31e33]. We
recently reported that plant-derived calanolide A and their
analogues have unique advantages in overcoming the existing
drug resistant viruses [8,9]. Using the same methods as in this
study, we showed that SOE inhibited not only RT inhibitor
resistant viruses (K103N, Y188L, and K103N/Y188L/G190A) but
also a protease inhibitor resistant primary strain (PI-2840).
Because RT and protease act after HIV entry, these results are
consistent with SOE as a new entry inhibitor. To explore the
potential of SOE for treating AIDS patients, a future welldesigned clinical trial should be conducted for in vivo efficacy evaluation. It is also necessary to purify the small
molecule compound from SOE with anti-HIV-1 activity.
In conclusion, in this study, we demonstrated that SOE
blocks entry by CCR5-tropic and CXCR4-tropic strains of
HIV-1. This blockade is HIV-1-specific because SOE does not
exhibit any activities against HIV-Lucþ viruses pseudotyped
with envelopes of VSV, SARS-CoV, and influenza. Interestingly, SOE acts directly on HIV-1 instead of cellular receptors or coreceptors. It also exhibits potency against
replication-competent HIV-1 strains resistant to specific
drugs targeting protease and RT activities. Our findings
therefore provide evidence for the potential use of SOE in
the prevention and treatment of HIV-1 infection, as well as
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in the search for small molecular compounds as specific
entry inhibitors.
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